We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Expression Informatics Companies Collaborate on Diagnostics of Age-Related Diseases

By LabMedica International staff writers
Posted on 22 Nov 2015
Print article
Affymetrix, Inc. (Santa Clara, CA, USA) and XRGenomics LTD (Nottingham, UK) have announced a partnership to collaborate on research and development of a new generation of diagnostic tests for age-related diseases.

According to the G8 Summit 2013, age-related diseases could bankrupt Western medicine by 2050. New solutions, such as earlier and more specific diagnosis, are required to help deliver care more effectively and efficiently. XRGenomics has utilized Affymetrix technology to develop novel gene expression-based signatures that enable translational research and biomarker test development activities in areas such as dementia, Alzheimer’s, and other age-related diseases. XRGenomics hopes that their biological age signature will become an important stratification tool for dementia research as early as 2017.

“Our unique approach to building diagnostics for complex diseases that become prevalent with age requires a high-throughput global transcriptomics solution such as that offered by expression array plates processed on the Affymetrix GeneTitan System—a platform that is scalable, accurate, and cost-effective,” said Prof. Jamie Timmons, PhD, chief scientific officer, XRGenomics, “To provide the next generation of clinically meaningful diagnostics for geriatric medicine, one must simultaneously assess multiple RNA scores, or markers for several age-related chronic diseases, to get an accurate picture of the patient. This is why we are so excited to be working with Affymetrix to optimize our RNA signatures in thousands of patients with cognitive impairment using the Affymetrix GeneTitan platform, which is extremely well suited to meet the technical demands of large-scale clinical trials.”

“There is a clear need to address the enormous challenge of managing complex age-related diseases that face healthcare systems globally. We believe that the work of XRGenomics will materially improve the research, diagnosis, and treatment of age-related diseases in the near future,” said Dan St. Louis, senior vice president, Expression Business Unit, Affymetrix, “Our GeneChip U133 Plus 2.0 array used by XRGenomics, particularly in its high-throughput automated format, continues to serve as a proven platform for clinical and translational researchers who need to analyze the expression profile of large clinical cohorts with the accuracy, reproducibility, speed, and cost effectiveness required to successfully develop complex RNA-based tests for clinical utility.”

Related Links:

Affymetrix
XRGenomics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more